Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · IEX Real-Time Price · USD
7.54
-0.60 (-7.37%)
At close: Jul 2, 2024, 4:00 PM
7.56
+0.02 (0.27%)
After-hours: Jul 2, 2024, 7:57 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Summit Therapeutics stock have an average target of 13.5, with a low estimate of 13 and a high estimate of 14. The average target predicts an increase of 79.05% from the current stock price of 7.54.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 3, 2024.
Analyst Ratings
The average analyst rating for SMMT stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $8 → $14 | Strong Buy | Maintains | $8 → $14 | +85.68% | Jun 3, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $7 → $13 | Strong Buy | Maintains | $7 → $13 | +72.41% | May 31, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | -7.16% | May 7, 2024 |
| Stifel | Stifel | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +6.10% | Mar 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Mar 19, 2020 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.26
from -0.01
EPS Next Year
-0.29
from -0.26
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 15.9M | 119.8M | 554.9M |
| Avg | n/a | n/a | 12.8M | 116.4M | 539.0M |
| Low | n/a | n/a | 9.8M | 111.8M | 517.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 833.6% | 376.8% |
| Avg | - | - | - | 807.0% | 363.2% |
| Low | - | - | - | 771.4% | 345.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.26 | -0.27 | -0.29 | -0.50 | -0.21 |
| Avg | -0.26 | -0.29 | -0.36 | -0.49 | -0.20 |
| Low | -0.25 | -0.31 | -0.43 | -0.47 | -0.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.